Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Company facts
| Company | Absci Corporation |
|---|---|
| Symbol | ABSI |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.41B (Massive market data, 2026-09-10) |
| Employees | 140 |
| Country | United States |
| Website | https://www.absci.com |
Trading — Absci Corporation
| Last price | $8.26 |
|---|---|
| Change | 0.24% |
| Previous close | $8.24 |
| Day range | $8.11 – $8.57 |
| 50-day average | $9.21 |
| 200-day average | $5.31 |
| Average volume | 4,559,561 |
Price basis: massive_snapshot_price · 2026-09-11T21:11:00.524183+00:00
Valuation and financial health
| Earnings per share | $-0.71 |
|---|---|
| Price / book | 5.75 |
| Enterprise value / EBITDA | -11.35 |
| Enterprise value / sales | 836.89 |
| Debt / equity | 0.00 |
| Current ratio | 10.63 |
| Dividend yield | 0.00% |
| Free cash flow | -$108.97M |
| Cash ratio | 5.50 |
| Enterprise value | $1.31B |
Reported 2026-09-10
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABSI are on the IntelTrends dashboard.